A5056247439- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Click Chemistry and Applications
- Nuclear Receptors and Signaling
- Immune Cell Function and Interaction
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- RNA Interference and Gene Delivery
- Epigenetics and DNA Methylation
- Cancer Immunotherapy and Biomarkers
- Hedgehog Signaling Pathway Studies
University of Florida
2022-2024
Florida State University
2023-2024
An effective cancer therapy requires killing cells and targeting the tumor microenvironment (TME). Searching for molecules critical multiple cell types in TME, we identified NR4A1 as one such molecule that can maintain immune suppressive TME. Here, establish a valid target immunotherapy describe first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 degrades within hours vitro exhibits long-lasting degradation tumors with an excellent safety profile....
Abstract An effective cancer therapy requires both killing cells and targeting tumor-promoting pathways or cell populations within the tumor microenvironment (TME). We purposely search for molecules that are critical multiple types in TME identified nuclear receptor subfamily 4 group A member 1 (NR4A1) as one such molecule. NR4A1 has been shown to promote aggressiveness of maintain immune suppressive TME. Using genetic pharmacological approaches, we establish a valid therapeutic target...
Abstract Interleukin 2 (IL-2) is the first identified cytokine and its interaction with receptors has been known to shape immune responses in many lymphoid or non-lymphoid tissues for more than four decades. Active T cells are primary cellular source IL-2 production epithelial have never considered major of under physiological conditions. It is, however, tempting speculate that could potentially express regulates intricate interactions between lymphocytes. Datamining our recently published...
Abstract Introduction: Modulating tumor-infiltrating immune cells is the key mission for development of cancer immunotherapy. However, current immunotherapies including immune-checkpoint inhibitors (ICI) have limited patient response rates and some with adverse effects, which drives us to seek novel targets improve immunotherapeutic efficiency. Based on recent literature our bioinformatic analysis, we believe that NR4A1 an ideal target immunotherapy due its important role in T cell...
Abstract Introduction: Melanoma originates from melanocytes within the epidermis and is one of most common cancers, with nearly 100000, new cases yearly. Despite numerous advancements in therapies to treat melanoma, a prevalent population patients still do not respond currently approved therapies. Recent studies have highlighted role transcription factor nuclear receptor subfamily 4 group A member 1 (NR4A1) melanoma for cancer survival, invasion, metastasis. NR4A1 also involved glucose...
Abstract Modulating tumor-infiltrating immune cells is the key mission for development of cancer immunotherapy. Based on recent literature and our bioinformatic analysis, nuclear receptor subfamily 4 group A member 1 (NR4A1) an ideal target immunotherapy due to its important role in T cell exhaustion, regulatory (Treg) function. Here we targets NR4A1 via proteolysis-targeting chimeric (PROTAC) technology, expecting achieve activation clearance. We designed synthesized over 80 PROTACs based...
Abstract An effective cancer therapy requires both killing cells and targeting tumor-promoting pathways or cell populations within the tumor microenvironment (TME). We purposely search for molecules that are critical multiple types identified nuclear receptor subfamily 4 group A member 1 (NR4A1) as one such molecule. NR4A1 has been shown to promote aggressiveness of maintain immune suppressive TME. Using genetic pharmacological approaches, we establish a valid therapeutic target therapy....